Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Provided is a one-component aqueous spray adhesive. The spray adhesive includes an aqueous chloroprene dispersion, where the increase of the Shore A hardness of the formed adhesive film in 0 to 10 hours accounts for equal to or more than 90% of the increase of the Shore A hardness of the formed adhesive film in 0 to 1000 hours; a styrene-acrylate copolymer dispersion having a solid content of 15% by weight to 25% by weight, relative to the total weight of solids of the aqueous chloroprene dispersion; a polyol ester without hydroxyl groups in an amount of 0.9% by weight to 3.8% by weight, relative to the total weight of the aqueous spray adhesive; and an amino acid in an amount of 4% by weight to 15% by weight, relative to the total weight of the aqueous chloroprene dispersion.

Abstract: A method for analyzing a correlation between rail transit and direct current (DC) magnetic bias of a transformer includes the steps of, A: obtaining a current of a feed cable and a DC magnetic bias current: measuring the feed cable current in rail transit and the DC magnetic bias current of a transformer in a power grid within a certain period by a monitoring apparatus; B: calculating a characteristic quantity of the feed current within the measurement period based on the obtained current of the feed cable; C: calculating a characteristic quantity of the DC magnetic bias current within the measurement period based on the DC magnetic bias current; and D: calculating a support degree and a confidence coefficient based on the calculated characteristic quantity of the feed current and the calculated characteristic quantity of the DC magnetic bias current, and generating a correlation rule.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Weigh-in-motion sensors comprise a beam including a plate with a load-bearing surface, and a tube portion including a base wall and a cover and defining a cavity therebetween. A sensing package is disposed within the cavity and is under pre-load with the cover and the base wall. The sensing package comprises a piezoelectric element. The base wall includes an aperture extending from a mounting surface to the cavity. The aperture includes a fastener therein to secure the sensing package within the cavity. The fastener is sized having a cross-section dimension taken through a center axis of the fastener that is greater than that of a cross-section dimension of the piezoelectric element taken along the fastener center axis. In an example, the fastener has a cross-section dimension sized about 10 percent or greater in dimension than that of the respective cross-section dimension of the piezoelectric element.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses substituted pyrrolo[1,2-c]pyrimidines, such as the compound which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: A method for analyzing a correlation between rail transit and direct current (DC) magnetic bias of a transformer includes the following steps: A: obtaining a current of a feed cable and a DC magnetic bias current: measuring the feed cable current in rail transit and the DC magnetic bias current of a transformer in a power grid within a certain period by a monitoring apparatus; B: calculating a characteristic quantity of the feed current within the measurement period based on the obtained current of the feed cable; C: calculating a characteristic quantity of the DC magnetic bias current within the measurement period based on the DC magnetic bias current; and D: calculating a support degree and a confidence coefficient based on the calculated characteristic quantity of the feed current and the calculated characteristic quantity of the DC magnetic bias current, and generating a correlation rule.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.